Immunicum meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i njurcancer
February 22, 2021 02:00 ET | Immunicum AB
Pressmeddelande 22 februari 2021 Immunicum meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i njurcancer - Medianöverlevnad för patientgruppen som behandlades...
Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
February 22, 2021 02:00 ET | Immunicum AB
Press Release 22 February 2021 Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer -- Median Overall Survival (OS) for the...
Logo  age001.jpg
Organicell Phase I/II Clinical Trial Update
August 18, 2020 07:00 ET | ORGANICELL REGENERATIVE MEDICINE, INC
MIAMI, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies,...
Cellectis Logo.png
To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of Directors
July 06, 2020 17:19 ET | Cellectis Inc.
NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) - André Choulika, Ph.D., Cellectis’ Chairman and CEO, announces that he will focus all his energy on...
Logo  age001.jpg
Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients
May 27, 2020 07:00 ET | ORGANICELL REGENERATIVE MEDICINE, INC
MIAMI, May 27, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies,...
Abeona Therapeutics.jpg
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
April 23, 2018 08:15 ET | Abeona Therapeutics Inc.
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
December 20, 2017 08:45 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies
October 16, 2017 08:26 ET | Abeona Therapeutics Inc.
Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programsCompany receives infusion of an additional $5 million from exercise of...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
October 11, 2017 08:19 ET | Abeona Therapeutics Inc
ABO-102 Patients Enrolled in Cohort 3 at 3E13 vg/kgAccelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underwayDay 30 results...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
October 06, 2017 08:25 ET | Abeona Therapeutics Inc
--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated...